Pancreatic Cancer	Aziz Ahmad, MDSurgical OncologyMills-Peninsula HospitalApril 23, 2011
Statistics10th most common cancer 4th leading cause of cancer death
Statistics80% of cases are adenocarcinomas from exocrine pancreasLess common exocrine tumors include:	IPMNMucinouscystadenocarcimomasIslet cell tumorsInsulin, glucagon, VIP, sandostatin, gastrin, nonsecretingMost common in black malesMedian age of diagnosis is 70
StatisticsRisk Factors:SmokingLow Vegtables & FruitsHigh red meatHigh sugar sweetened drinksChronic pancreatitis (especially hereditary)DiabetesObesityGenetic (5-10%)Family history, Puetz-Jerghers, HNPCC, FAP, Ataxia-Telangiectasia, Hereditary Pancreatitis, FAMMM-PC
PresentationNonspecific symptomsTumors of body and tail (25%)Pain and weight lossTumors of the Head (75%)Jaundice, steatohrrea, weight loss, Couvoirsier’s sign, painLabsIncreased LFTs, elevated CA19-9
ImagingUltrasoundBile duct distensionMass CT scan with IV contrastQuality of imaging continues to improveTriple phase CT (pancreas protocol) 90% accurate at finding lesionsEndoscopic ultrasoundHelp find lesions not seen on CTHelp determine resectabilityExcellent way to get biopsy	ERCPTherapeutic as well as diagnostic
TreatmentNeeds to be multimodalPrimary care, radiology, gastroenterology, surgery, & oncologySurgery is the only cureCure only in those with complete resectionsOtherwise outcome is poor with surgery
TreatmentFinding lesions early (hardest job)High index of suspicion by primary careModern CT technology Gastroenterologist with specialized skill in ERCP and EUSSurgeons with experience in pancreatic surgeryRadiation/medical oncology up to date with standard of care and knowledge of any promising clinical trials
What is resectable?Tumors localized to pancreas 15-20% of patientsLocally advanced disease in patients with vascular involvement of less than 50% of portal vein Or lymph node spread that is limited 10-15%Resection contraindicated in patients:>50% involvement of portal veinInvasion or encasement of SMA (or hepatic artery)
Non Surgical CandidatesPalliative chemoradiationClinical trialsMedian survival is about 8 monthsPalliative endoscopic or surgical procedures5-10% locally advanced patients not initially surgical candidates can be downstaged
General Survival DataOverall prognosis seems dismal70-80% of patients present as inoperable due to metastatic  disease or locally advanced diseaseMedian survival only 4-6 months20-30% are operable with localized or resectable locally advanced diseaseSuccessful operation can give five year survivals from 20-30%
Surgical ProceduresTumors of the Body and TailLaparoscopic distal pancreatectomyRemoval of body & tail of pancreasspleen
Surgical ProceduresHead of the pancreas: Whipple ProcedureRemoval of:Distal stomachDuodenum and proximal jejunemHead of pancreasGallbladder and common bile duct
ComplicationsWhipple ProcedurebleedingGastroparesisPancreatic duct leakBile duct leakDiabetesmalabsorptionDistal pancreatectomyBleedingPancreatic duct leakMalabsorptiondiabetes
ComplicationsParticularly Whipple procedure thought to have poor surgical outcomesMills-Peninsula experience in the last 40 Whipples:	5%  60 day mortalityEven in patients that recur after 2-3 years, quality of life is excellent before symptoms of disease return
Adjuvant TreatmentMost patients go on to get adjuvant treatmentGemcitibine based chemotherapyRadiation to the surgical bedEven with this 70-80% of patients recur
Why Does it Recur?Pancreas with rich vascular and lymphatic supplyEarly lymph node spreadMicroscopic at the time of surgeryCurrently best chemo with only 25-30% response rate
ConclusionSo at this time the best answer is to catch the disease earlyIn those that you can detect disease early, all hope is not lostWith an operation, you not only give a chance for cure, but you give hope

Pancreatic Cancer

  • 1.
    Pancreatic Cancer Aziz Ahmad,MDSurgical OncologyMills-Peninsula HospitalApril 23, 2011
  • 2.
    Statistics10th most commoncancer 4th leading cause of cancer death
  • 3.
    Statistics80% of casesare adenocarcinomas from exocrine pancreasLess common exocrine tumors include: IPMNMucinouscystadenocarcimomasIslet cell tumorsInsulin, glucagon, VIP, sandostatin, gastrin, nonsecretingMost common in black malesMedian age of diagnosis is 70
  • 4.
    StatisticsRisk Factors:SmokingLow Vegtables& FruitsHigh red meatHigh sugar sweetened drinksChronic pancreatitis (especially hereditary)DiabetesObesityGenetic (5-10%)Family history, Puetz-Jerghers, HNPCC, FAP, Ataxia-Telangiectasia, Hereditary Pancreatitis, FAMMM-PC
  • 5.
    PresentationNonspecific symptomsTumors ofbody and tail (25%)Pain and weight lossTumors of the Head (75%)Jaundice, steatohrrea, weight loss, Couvoirsier’s sign, painLabsIncreased LFTs, elevated CA19-9
  • 6.
    ImagingUltrasoundBile duct distensionMassCT scan with IV contrastQuality of imaging continues to improveTriple phase CT (pancreas protocol) 90% accurate at finding lesionsEndoscopic ultrasoundHelp find lesions not seen on CTHelp determine resectabilityExcellent way to get biopsy ERCPTherapeutic as well as diagnostic
  • 7.
    TreatmentNeeds to bemultimodalPrimary care, radiology, gastroenterology, surgery, & oncologySurgery is the only cureCure only in those with complete resectionsOtherwise outcome is poor with surgery
  • 8.
    TreatmentFinding lesions early(hardest job)High index of suspicion by primary careModern CT technology Gastroenterologist with specialized skill in ERCP and EUSSurgeons with experience in pancreatic surgeryRadiation/medical oncology up to date with standard of care and knowledge of any promising clinical trials
  • 9.
    What is resectable?Tumorslocalized to pancreas 15-20% of patientsLocally advanced disease in patients with vascular involvement of less than 50% of portal vein Or lymph node spread that is limited 10-15%Resection contraindicated in patients:>50% involvement of portal veinInvasion or encasement of SMA (or hepatic artery)
  • 10.
    Non Surgical CandidatesPalliativechemoradiationClinical trialsMedian survival is about 8 monthsPalliative endoscopic or surgical procedures5-10% locally advanced patients not initially surgical candidates can be downstaged
  • 11.
    General Survival DataOverallprognosis seems dismal70-80% of patients present as inoperable due to metastatic disease or locally advanced diseaseMedian survival only 4-6 months20-30% are operable with localized or resectable locally advanced diseaseSuccessful operation can give five year survivals from 20-30%
  • 12.
    Surgical ProceduresTumors ofthe Body and TailLaparoscopic distal pancreatectomyRemoval of body & tail of pancreasspleen
  • 13.
    Surgical ProceduresHead ofthe pancreas: Whipple ProcedureRemoval of:Distal stomachDuodenum and proximal jejunemHead of pancreasGallbladder and common bile duct
  • 14.
    ComplicationsWhipple ProcedurebleedingGastroparesisPancreatic ductleakBile duct leakDiabetesmalabsorptionDistal pancreatectomyBleedingPancreatic duct leakMalabsorptiondiabetes
  • 15.
    ComplicationsParticularly Whipple procedurethought to have poor surgical outcomesMills-Peninsula experience in the last 40 Whipples: 5% 60 day mortalityEven in patients that recur after 2-3 years, quality of life is excellent before symptoms of disease return
  • 16.
    Adjuvant TreatmentMost patientsgo on to get adjuvant treatmentGemcitibine based chemotherapyRadiation to the surgical bedEven with this 70-80% of patients recur
  • 17.
    Why Does itRecur?Pancreas with rich vascular and lymphatic supplyEarly lymph node spreadMicroscopic at the time of surgeryCurrently best chemo with only 25-30% response rate
  • 18.
    ConclusionSo at thistime the best answer is to catch the disease earlyIn those that you can detect disease early, all hope is not lostWith an operation, you not only give a chance for cure, but you give hope